{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:47:20Z","timestamp":1787330840477,"version":"build-2736575974"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.lungcan.2022.01.016","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T20:54:05Z","timestamp":1643057645000},"page":"91-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition"],"prefix":"10.1016","volume":"165","author":[{"given":"Luca","family":"Cantini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Laniado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2022.01.016_b0005","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0010","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/s41416-021-01462-2","article-title":"Biological basis for novel mesothelioma therapies","volume":"125","author":"Obacz","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fonc.2020.00343","article-title":"Emerging treatments for malignant pleural mesothelioma: where are we heading?","volume":"10","author":"Cantini","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0025","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, japanese phase ii study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0030","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"French cooperative thoracic I. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0035","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2022.01.016_b0040","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.21037\/tlcr-19-686","article-title":"Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program","volume":"9","author":"Cantini","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.lungcan.2022.01.016_b0045","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0050","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0055","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2022.01.016_b0060","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lungcan.2022.01.016_b0065","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","article-title":"Mesothelioma epidemiology, carcinogenesis, and pathogenesis","volume":"9","author":"Yang","year":"2008","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0070","doi-asserted-by":"crossref","unstructured":"Lorenzini E, Ciarrocchi A, Torricelli F. Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations. J Clin Med 2021;10.","DOI":"10.3390\/jcm10112470"},{"key":"10.1016\/j.lungcan.2022.01.016_b0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0080","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1164\/rccm.201608-1755CI","article-title":"Checkpoint blockade in lung cancer and mesothelioma","volume":"196","author":"Lievense","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0085","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic potential of complex chromosomal rearrangements in mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0090","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1186\/s12885-021-08548-3","article-title":"Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma","volume":"21","author":"Lai","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2021.08.079","article-title":"Tumor junction burden and antigen presentation as predictors of survival in mesothelioma treated with immune checkpoint inhibitors","author":"Kosari","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0100","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2022.01.016_b0105","article-title":"Integrative tumor and immune cell multi-omic analyses predict response to immune checkpoint blockade in melanoma","volume":"1","author":"Anagnostou","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0110","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-019-0592-2","article-title":"Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer","volume":"25","author":"Joshi","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0115","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0120","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0125","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","article-title":"Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2022.01.016_b0130","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lungcan.2022.01.016_b0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13073-021-00931-w","article-title":"Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma","volume":"13","author":"Meiller","year":"2021","journal-title":"Genome Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lungcan.2022.01.016_b0145","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the treatment of malignant pleural mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003032","article-title":"Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy","volume":"9","author":"Harber","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041041","article-title":"Heterogeneity in immune cell content in malignant pleural mesothelioma","volume":"19","author":"Minnema-Luiting","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2022.01.016_b0160","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"685\u2013700","key":"10.1016\/j.lungcan.2022.01.016_b0165","article-title":"The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2022.01.016_b0170","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2022.01.016_b0175","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","article-title":"VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy","volume":"2","author":"Lines","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0180","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2022.01.016_b0185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001601","article-title":"Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification","volume":"9","author":"Alay","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0190","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbrc.2006.03.018","article-title":"Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy","volume":"343","author":"Needham","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lungcan.2022.01.016_b0195","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/bjc.2017.269","article-title":"Evaluating the effect of immune cells on the outcome of patients with mesothelioma","volume":"117","author":"Chee","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0200","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2022.01.016_b0205","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/798467","article-title":"Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity","volume":"2010","author":"Veltman","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0210","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2020.01963","article-title":"Granulocytic myeloid-derived suppressor cells as negative regulators of anticancer immunity","volume":"11","author":"Kramer","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0215","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","article-title":"Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma","volume":"14","author":"Salaroglio","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2022.01.016_b0220","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1638211","article-title":"Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes","volume":"8","author":"Klampatsa","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lungcan.2022.01.016_b0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106742","article-title":"Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma","volume":"9","author":"Cornelissen","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.lungcan.2022.01.016_b0230","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.lungcan.2015.03.013","article-title":"Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma","volume":"88","author":"Cornelissen","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0235","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0240","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.lungcan.2013.02.017","article-title":"Tumor-associated macrophages in thoracic malignancies","volume":"80","author":"Lievense","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0245","doi-asserted-by":"crossref","unstructured":"Ollila H, Ilonen I, Mayranpaa M, Pellinen T. Type M1 and Type M2 Macrophages Are Associated With Patient Survival in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology 2021;16: S871-S871.","DOI":"10.1016\/j.jtho.2021.08.078"},{"key":"10.1016\/j.lungcan.2022.01.016_b0250","doi-asserted-by":"crossref","unstructured":"Magkouta SF, Vaitsi PC, Pappas AG, Iliopoulou M, Kosti CN, Psarra K, Kalomenidis IT. CSF1\/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy. Cancers (Basel) 2021;13.","DOI":"10.3390\/cancers13112546"},{"key":"10.1016\/j.lungcan.2022.01.016_b0255","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1158\/2326-6066.CIR-16-0309","article-title":"Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy","volume":"5","author":"Dammeijer","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0260","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bjc.6605814","article-title":"Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma","volume":"103","author":"Veltman","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0265","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1164\/rccm.200501-057OC","article-title":"Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells","volume":"171","author":"Hegmans","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0270","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0275","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human","volume":"24","author":"Aerts","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0280","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2021.05.004","article-title":"CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials","volume":"157","author":"Chintala","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0285","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2022.01.016_b0290","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-021-03235-6","article-title":"Lipid signalling enforces functional specialization of T(reg) cells in tumours","volume":"591","author":"Lim","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2022.01.016_b0295","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0300","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2020.10.031","article-title":"High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients","volume":"144","author":"Cantini","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0305","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0310","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0315","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0320","doi-asserted-by":"crossref","unstructured":"Deepti V, Adrienne A, Subba D, Patrick HL, Mark MA. Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM). Journal of Clinical Oncology 2019;37: 8549-8549.","DOI":"10.1200\/JCO.2019.37.15_suppl.8549"},{"key":"10.1016\/j.lungcan.2022.01.016_b0325","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0330","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","author":"Popat","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103040","article-title":"Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials","volume":"62","author":"Mankor","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lungcan.2022.01.016_b0340","doi-asserted-by":"crossref","unstructured":"Marcq E, Van Audenaerde JRM, De Waele J, Merlin C, Pauwels P, van Meerbeeck JP, Fisher SA, Smits ELJ. The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3. Cancers (Basel) 2021;13.","DOI":"10.3390\/cancers13020282"},{"key":"10.1016\/j.lungcan.2022.01.016_b0345","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0350","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","article-title":"PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy","volume":"4","author":"Sasikumar","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0355","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0360","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0365","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003288","article-title":"JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma","volume":"9","author":"Miyamoto","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0370","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2022.01.016_b0375","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"French cooperative thoracic I. bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2022.01.016_b0380","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0385","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.19.00269","article-title":"Phase II trial of cediranib in combination with cisplatin and pemetrexed in chemotherapy-naive patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"37","author":"Tsao","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0390","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0395","doi-asserted-by":"crossref","unstructured":"Tsao A, Qian L, Cetnar J, Sepesi B, Gomez D, Wrangle J, Simon G, Mott F, Hall R, Santana-Davila R, Koczywas M, Redman M, Kelly K. S1619 A Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and Maintenance for Resectable Pleural Mesothelioma. Journal of Thoracic Oncology 2021;16: S870-S870.","DOI":"10.1016\/j.jtho.2021.08.076"},{"key":"10.1016\/j.lungcan.2022.01.016_b0400","first-page":"545","article-title":"Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies","volume":"4","author":"Simone","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0405","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/439752","article-title":"The confluence of stereotactic ablative radiotherapy and tumor immunology","volume":"2011","author":"Finkelstein","year":"2011","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0410","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","article-title":"Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial","volume":"16","author":"Golden","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0415","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0420","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lungcan.2022.01.016_b0425","doi-asserted-by":"crossref","first-page":"12468","DOI":"10.18632\/oncotarget.3487","article-title":"Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2022.01.016_b0430","first-page":"85","article-title":"Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab","volume":"27","author":"Mampuya","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.lungcan.2022.01.016_b0435","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/j.jtho.2019.05.013","article-title":"Proton beam therapy and immune checkpoint inhibitors in malignant pleural mesothelioma","volume":"14","author":"McCusker","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0440","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/B978-0-12-800249-0.00002-0","article-title":"Therapeutic cancer vaccines","volume":"121","author":"Schlom","year":"2014","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0445","doi-asserted-by":"crossref","unstructured":"Apostolopoulos V. Cancer Vaccines: Research and Applications. Cancers (Basel) 2019;11.","DOI":"10.3390\/cancers11081041"},{"key":"10.1016\/j.lungcan.2022.01.016_b0450","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.omto.2019.03.007","article-title":"Enhancing dendritic cell therapy in solid tumors with immunomodulating conventional treatment","volume":"13","author":"Belderbos","year":"2019","journal-title":"Mol. Ther. Oncolyt."},{"key":"10.1016\/j.lungcan.2022.01.016_b0455","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.3389\/fimmu.2018.02759","article-title":"Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy","volume":"9","author":"van Gulijk","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0460","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0465","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","article-title":"A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial","volume":"8","author":"Belderbos","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0470","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lungcan.2022.01.016_b0475","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0480","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/1471-2407-12-615","article-title":"Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1)","volume":"12","author":"Petrausch","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0485","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0490","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","article-title":"Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells","volume":"393","author":"Klampatsa","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.lungcan.2022.01.016_b0495","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.lungcan.2012.03.008","article-title":"Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma","volume":"77","author":"Al-Taei","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0500","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1158\/1078-0432.CCR-12-0628","article-title":"CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma","volume":"18","author":"Rivera","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0505","doi-asserted-by":"crossref","unstructured":"Klampatsa A, Haas AR, Moon EK, Albelda SM. Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). Cancers (Basel) 2017;9.","DOI":"10.3390\/cancers9090115"},{"key":"10.1016\/j.lungcan.2022.01.016_b0510","doi-asserted-by":"crossref","unstructured":"Prasad SA, Marjorie Glass Z, Valerie WR, Roisin OC, Amy Z, Daniel N, Erin M, Navin C, John M, Waseem C, Elizabeth H, Claudia D, John P, Alain V, Shanu M, Stephen Barnett S, David Randolph J, Renier JB, Isabelle R, Michel S. Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent. Journal of Clinical Oncology 2019;37: 2511-2511.","DOI":"10.1200\/JCO.2019.37.15_suppl.2511"},{"key":"10.1016\/j.lungcan.2022.01.016_b0515","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz253.052","article-title":"A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells","volume":"30","author":"Curioni","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0520","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2020.10.007","article-title":"Oncolytic herpesvirus therapy for mesothelioma \u2013 A phase I\/IIa trial of intrapleural administration of HSV1716","volume":"150","author":"Danson","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2022.01.016_b0525","doi-asserted-by":"crossref","unstructured":"Peikert T, Mandrekar S, Mansfield A, Van Keulen V, Albelda S, Aderca S, Carlson S, Dietz A, Gustafson M, Kratzke R, Lowe V, Maldonado F, Molina J, Pate M, Roden A, Sun J, Tan A, Tippmann-Peikert M, Galanis E. Intrapleural Modified Vaccine Strain Measles Virus Therapy for Patients with Malignant Pleural Mesothelioma. Journal of Thoracic Oncology 2017;12: S296-S296.","DOI":"10.1016\/j.jtho.2016.11.305"},{"key":"10.1016\/j.lungcan.2022.01.016_b0530","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","article-title":"A trial of intrapleural adenoviral-mediated Interferon-\u03b12b gene transfer for malignant pleural mesothelioma","volume":"184","author":"Sterman","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0535","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFN\u03b1 combined with chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0540","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1084\/jem.20111171","article-title":"Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans","volume":"208","author":"Caskey","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lungcan.2022.01.016_b0545","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1158\/1078-0432.CCR-13-2781","article-title":"Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors","volume":"20","author":"Nagato","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0550","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","article-title":"A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2022.01.016_b0555","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1245\/s10434-017-6266-8","article-title":"Metastasectomy for tumor-infiltrating lymphocytes: an emerging operative indication in surgical oncology","volume":"25","author":"Crompton","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.lungcan.2022.01.016_b0560","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000668","article-title":"Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma","volume":"8","author":"Borch","year":"2020","journal-title":"J. ImmunoTher. Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:59:12Z","timestamp":1759237152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":112,"alternative-id":["S0169500222000289"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.01.016","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}